Guardian Pharmacy Services vs National HealthCare
GRDN and NHC side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GRDN and NHC compare
Guardian Pharmacy Services and National HealthCare are about the same size, with market caps of $3.2B and $3.3B.
National HealthCare grew revenue faster over the last twelve months (5.6% versus 4.9% for Guardian Pharmacy Services).
National HealthCare keeps more of each dollar of sales as profit, with a net margin of 7.2% compared with 5.1% at Guardian Pharmacy Services.
National HealthCare pays a dividend yielding 1.2%; Guardian Pharmacy Services does not pay one.
National HealthCare scores higher on the StockData Score (13 against 9 for Guardian Pharmacy Services), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GRDN | NHC |
|---|---|---|
| Size and price | ||
| Market cap | $3.2B | $3.3B |
| Share price | $49.98 | $210.38 |
| Change, 1 year | 68.0% | 60.9% |
| Change, 5 years | – | 201% |
| Beta (5Y) | 0.56 | 0.46 |
| Employees | 3,600 | 15K |
| StockData Score | ||
| Total score | 9 | 13 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 1 | 3 (better) |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 29.1× |
| P/S | 2.2× | 2.1× (better) |
| P/B | – | 2.9× |
| EV/EBITDA | 26.0× | 18.3× (better) |
| PEG | – | 0.39 |
| Fair value | $19.44 | $152.75 |
| Margin of safety | −157% | −37.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 4.9% | 5.6% (better) |
| Revenue growth, 5Y average | – | 8.1% |
| Net income growth (TTM) | 85.8% (better) | 13.2% |
| EPS growth (TTM) | – | 11.7% |
| EPS growth, 5Y average | – | 23.0% |
| Profitability | ||
| Gross margin | 22.4% | – |
| Operating margin | 6.5% | 9.8% (better) |
| Net margin | 5.1% | 7.2% (better) |
| Return on equity | – | 10.5% |
| Return on invested capital | – | 9.3% |
| Financial health | ||
| Debt / equity | – | 0.45 |
| Net debt / EBITDA | – | 2.13 |
| Interest coverage | 145× (better) | 19.2× |
| Current ratio | 1.65 (better) | 1.48 |
| Altman Z-score | 13.18 (better) | 3.81 |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | – | 1.2% |
| Payout ratio | – | 35.2% |
| Years of dividend growth | – | 12 |
| Dividend growth, 5Y average | – | 4.0% |
| Buyback yield | −0.96% | 0.13% (better) |
| Shareholder yield | −0.96% | 1.4% (better) |
| Ownership | ||
| Held by institutions | 46.6% | 65.3% |
| Held by insiders | 43.6% | 9.3% |
| Insider net buying, 12 months | −$419M | −$9.1M (better) |
| Short interest, % of float | 6.2% | 5.4% |
Go deeper
- GRDN stock overview
- GRDN income statement
- GRDN valuation and score
- NHC stock overview
- NHC income statement
- NHC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.